Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

Abstract Background Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1–2 trials of adoptive cell therapy with tumor-infiltrating lymphocytes…#nationalcenterforcancerimmunetherap #hospitalpharmacyandclinicalchemistry #dutchcancersociety #nejmorg #qualityassuranceandqualitycontrol #marjoleindelfos #anjafvanderwal #divisionofmolecularoncologyandimmun #loespronk #haanen
Source: Reuters: Health - Category: Consumer Health News Source Type: news